Belgian biotech Augustine gets $85M for neuro and cardiometabolic pills

Kyle LaHucik

Senior Reporter

Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take on Charcot-Marie-Tooth disease, neurodegenerative conditions and cardiometabolic disorders.

Two of Europe’s leading biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Belgian biotech Augustine gets $85M for neuro and cardiometabolic pills

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui

Another immunology biotech emerges as Hillstar takes flight with $67M

Kezar toplines small Phase 2a dataset in autoimmune liver disease

Ophthalmology startup Character Biosciences gets $93M for genetics-based approach

AbbVie files trade secrets suit against ADC competitor

Bel­gian biotech Au­gus­tine gets $85M for neu­ro and car­diometa­bol­ic pills

Senior Reporter

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Belgian biotech Augustine gets $85M for neuro and cardiometabolic pills